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EDITORIAL

Treating Intellectual Disability; Look for
Creatine Peaks in the Brain
Can. J. Neurol. Sci. 2011; 38: 669-670

Intellectual disability (ID) is a heavy burden both on an
individual and society, as its effects last a lifetime. Impairments
due to cognitive subnormality (IQ<70) carry social,
psychological and economic consequences. A prevalence rate of
3-4/1000 individuals is estimated, and in a majority of cases no
definite cause is identifiable1. Genetic factors ( chromosomal
aberrations, microdeletions, single gene defects together)
account for 25-40% of ID and the majority are not treatable even
if diagnosis is made early2. However, single gene disorders
categorized under the rubric of inborn errors of metabolism offer
unique opportunities where early diagnosis and institution of
specific therapy can go a long way to improve neurological
outcomes for affected individuals3. The first and perhaps most
striking success for such interventions was made with
phenylketonuria, where the reduction of dietary phenylalanine
made a significant impact on the outcome of a disorder that was
once considered a major cause of severe ID and neurological
handicap. Since that initial step towards recognition of
treatable/preventable causes, it has been estimated that there are
more than 70 diagnosable conditions that are considered as
potentially treatable. One group of disorders, the "cerebral
creatine deficiency syndromes (CCDS)" are gaining increasing
prominence.
In this issue of the Journal, Hinnell et al bring to our attention
the condition of guanidinoacetate methyltransferase (GAMT)
deficiency diagnosed in adulthood in two siblings where the
diagnosis was made after extensive investigations4. In retrospect,
they point out in their discussion, that biochemical clues to this
condition had been missed. The condition could have also been
diagnosed earlier by using the non-invasive technique of
magnetic resonance spectroscopy.
The first report of a patient with CCDS was described by
Sylvia Stockier and colleagues then at the University of
Gottingen in 19945. In that paper, the authors made several
important observations; 1) cerebral depletion of creatine was
responsible for the symptoms of a hitherto described
neurological condition manifesting with extrapyramidal
symptoms, 2) creatine depletion in the brain could be easily
identified using magnetic resonance spectroscopy, a noninvasive methodology, and 3) the condition could be corrected
with arginine restriction, supplementation of ornithine and
creatine monohydrate.
Since that initial description, three distinct biochemical
disorders caused by mutations in genes that encode enzymes of
creatine biosynthesis and transport have been identified. These
are guanidinoacetate methyltransferase deficiency, L-arginineglycine amidinotransferase (AGAT), and creatine transporter
(SLC6A8 deficiency)6. It has been shown that CCDS can
account for a prevalence of nearly 1.9% of sporadic cases of
mental retardation in boys and an even higher proportion in
familial cases7. The greater impact on males is accounted for by
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location of the creatine transporter gene is on the X chromosome.
Each of these three conditions can be associated with intellectual
disability and a highly variable neurological phenotype
associated with epileptic seizures, neurobehavioral symptoms of
autism, and movement disorders. The common denominator for
each of the three disorders is cerebral creatine depletion.
Creatine depletion in the brain can be identified using the
technique of magnetic resonance spectroscopy which only takes
a few minutes of additional time in routine clinical magnetic
resonance imaging (MRI) scanners now available in most major
medical centres 8 . The spectral tracing obtained from brain
volumes ranging from 1-8 cc gives enough information to
quantify several cerebral metabolites including; creatine (Cr),
choline (Ch), and N-acetyl aspartate (NAA), lactate,
myoinositol, and glucose9. The absence of a creatine peak in the
presence of normal NAA and Ch peaks is a considered sine qua
non of CCDS. Females with SLC6A8 deficiency are the
exception as they show only a partial depletion of the cerebral
creatine pool. 810
Biochemical confirmation begins with the estimation of
guanidine acetate, creatine and creatinine in blood and urine.
Low plasma creatinine estimated by the appropriate quantitative
methods also serves as a useful biochemical marker 1 '. However
assays of creatinine in 24 hour urine samples may be misleading
in young children and infants with low muscle mass, factors that
may be reflected in low values10. Hinnell et al further point out
that the assay of creatinine in the serum should be carried out by
high performance liquid chromatography or stable isotope
dilution liquid chromatography electrospray mass spectrometry
(ID LC-MSMS), as conventional laboratory methods may over
estimate creatinine values when they are at low levels giving rise
to spuriously normal values4.
Molecular diagnostic testing is currently available for each of
the three disorders. Of the three conditions, creatine transporter
deficiency is X linked recessive, while the other two are
inherited as autosomal recessive. Treatment for GAMT consists
of arginine restriction, creatine monohydrate and ornithine
supplementation6 •'2.
Published clinical data suggest that even when the diagnosis
is delayed, considerable improvements are seen in clinical
symptom control of seizures and behavior. However intellectual
disability does not appear to consistently improve in all patients
in whom the diagnosis was delayed13. In AGAT deficiency,
again, creatine supplementation leads to improvements in
severity of clinical symptoms. Whether all of the manifestations
of CCDS are preventable following early diagnosis and
treatment is still under investigation10 Symptoms in creatine
transporter deficiency have proven most resistant to treatment
for obvious reasons 8 . In the absence of the creatine transporter,
creatine is unable to get past the blood brain barrier. However it
is heartening to note that in a female patient with SLC6A8
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deficiency and intractable epilepsy, supplementation with
creatine monohydrate, L-arginine and L-glycine resulted in the
complete resolution of seizures14.
The paper by Hinnell et al, draws our attention to the
phenotypic variability in presentations of CCDS, further
emphasizing the need for clinicians to consider this group of
disorders in the differential diagnosis of patients with intellectual
disability and neurological handicap4. Clearly timely diagnosis
and potential treatment options that become available once
diagnosis is established, promise substantial improvements in the
quality of life for affected individuals with CCDS. Thus,
clinicians (pediatricians neurologists), biochemical geneticists,
and neuroradiologists need to recognize the value of
incorporating MRS techniques in the investigation of every
patient who undergoes an evaluation for intellectual disability
(with or without additional neurological symptoms) so that
cerebral creatine depletion does not go unrecognized15.
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